Asio Capital LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 25.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,518 shares of the biopharmaceutical company's stock after purchasing an additional 724 shares during the period. Asio Capital LLC's holdings in Regeneron Pharmaceuticals were worth $2,506,000 at the end of the most recent quarter.
Several other institutional investors have also recently modified their holdings of REGN. First Citizens Bank & Trust Co. raised its position in Regeneron Pharmaceuticals by 30.7% during the 4th quarter. First Citizens Bank & Trust Co. now owns 362 shares of the biopharmaceutical company's stock worth $258,000 after buying an additional 85 shares during the last quarter. Linden Thomas Advisory Services LLC raised its holdings in shares of Regeneron Pharmaceuticals by 8.6% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 3,055 shares of the biopharmaceutical company's stock worth $2,176,000 after purchasing an additional 241 shares during the last quarter. Exchange Traded Concepts LLC raised its holdings in shares of Regeneron Pharmaceuticals by 53.2% during the fourth quarter. Exchange Traded Concepts LLC now owns 6,159 shares of the biopharmaceutical company's stock worth $4,387,000 after purchasing an additional 2,139 shares during the last quarter. Greater Midwest Financial Group LLC lifted its position in Regeneron Pharmaceuticals by 23.3% during the fourth quarter. Greater Midwest Financial Group LLC now owns 3,108 shares of the biopharmaceutical company's stock valued at $2,214,000 after purchasing an additional 588 shares during the period. Finally, Brighton Jones LLC grew its position in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after purchasing an additional 686 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ REGN opened at $675.79 on Friday. The stock has a market cap of $74.26 billion, a PE ratio of 16.72, a P/E/G ratio of 1.59 and a beta of 0.10. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $666.25 and a 12-month high of $1,211.20. The company has a 50-day moving average of $727.19 and a 200 day moving average of $937.77.
Several equities analysts have recently issued reports on the company. Citigroup decreased their price objective on Regeneron Pharmaceuticals from $895.00 to $795.00 and set a "neutral" rating for the company in a report on Tuesday, January 14th. Morgan Stanley decreased their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating for the company in a report on Friday, November 1st. Oppenheimer cut their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating for the company in a report on Wednesday, November 6th. Evercore ISI lowered their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating on the stock in a report on Thursday, October 24th. Finally, Sanford C. Bernstein cut their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $1,015.38.
Read Our Latest Analysis on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.